01 9Cancidas
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 214
2019 Revenue in Millions : 249
Growth (%) : -14
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 212
2020 Revenue in Millions : 213
Growth (%) : 0
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 174
2021 Revenue in Millions : 212
Growth (%) : -18
Main Therapeutic Indication : Anti-fungal
Currency : USD
2015 Revenue in Millions : 681
2014 Revenue in Millions : 573
Growth (%) : -16%
Main Therapeutic Indication : Anti-fungal
Currency : USD
2014 Revenue in Millions : 3.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2016 Revenue in Millions : 558
2015 Revenue in Millions : 572
Growth (%) : -2
Main Therapeutic Indication : Anti-fungal
Currency : USD
2017 Revenue in Millions : 422
2016 Revenue in Millions : 558
Growth (%) : -24
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2018 Revenue in Millions : 326
2017 Revenue in Millions : 422
Growth (%) : -23%
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 249
2018 Revenue in Millions : 326
Growth (%) : -24
LOOKING FOR A SUPPLIER?